The WHO’s nicotine pouch report is somewhat right about the marketing problem but uneasy about the harm-reduction problem.

It highlights a typical commercial style: playful, vibrant packaging; influencer marketing; sports sponsorships; aspirational branding; and trendy language. It also features flavors, discreet formats, and tobacco-free language. These strategies can lower the symbolic barrier to nicotine use, especially for adolescents and young never-smokers.

But the report struggles with the harder ambiguity: the same attributes that may attract never-users can also help adult smokers move away from cigarettes.

That is the fault line. Nicotine pouches are not harmless. But they are also not combustible cigarettes. Public health can readily recognize the first fact. It still hesitates before the second.

Why It Matters

For decades, tobacco control was organized around a clear enemy: the cigarette. It joined nicotine, combustion, addiction, disease, death, and industry manipulation in a single object.

Nicotine pouches disrupt that clarity. They deliver nicotine without tobacco leaf, without smoke, without smell, and without combustion, the mechanism responsible for most smoking-related harm.

The WHO report responds mainly through the grammar of precaution. That is understandable. Youth uptake matters. Marketing matters. Dependence matters.

But precaution becomes incomplete when it cannot accommodate relative risk.

If public health treats all nicotine products as extensions of the cigarette, it may protect the moral clarity of tobacco control while weakening its capacity to reduce harm among smokers who have not quit.

Evidence at a Glance

• The WHO report warns that nicotine pouch marketing is expanding faster than regulation.

• Its central concern is commercial capture: flavors, packaging, digital influence, sports sponsorships, and “tobacco-free” branding.

• In Great Britain, nicotine pouch use among 16-to-24-year-olds rose from 0.7% in January 2022 to 4.0% in March 2025; among young men, it reached 7.5%.

• The same data show overlap with smoking and vaping, making it difficult to reduce the trend to simple initiation.

• In the United States, youth pouch use among 10th- and 12th-grade students increased from 2023 to 2024, alongside dual use with e-cigarettes.

• The unresolved question is whether growth reflects initiation, experimentation, dual use, substitution, cessation attempts, or all of these at once.

Why This Matters for Policy

Scientific

• The key question is not whether nicotine pouches are safe. They are not risk-free. Nothing is.

• The key question is: safe compared with what?

• Compared with abstinence, pouches carry risk. Compared with combustible cigarettes, the toxicological distance is substantial. The main devastation caused by smoking comes from combustion: tar, carbon monoxide, ultrafine particles, and thousands of toxic compounds generated by burning tobacco.

• The WHO report sees absolute risk clearly. It is less comfortable with relative risk.

Regulatory

• The report reflects a regulatory imagination still shaped by the cigarette.

• That creates a problem. If pouches are regulated only as a youth threat, adult smokers may lose access to lower-risk alternatives. If they are promoted without guardrails, youth uptake may expand.

• The task is not to choose one reality and deny the other. It is to regulate by user, product, risk, and context.

• That means strict age controls, marketing restrictions, product standards, surveillance, and honest communication about comparative risk.

Equity Implications

• The missing figure in much of the WHO’s framing is the persistent adult smoker.

• As smoking declines, it becomes more concentrated among people facing psychological distress, low income, precarious work, interrupted schooling, and social exclusion. For many of them, quitting is not simply a matter of information or willpower.

• A public-health model that rejects lower-risk alternatives because they fall short of abstinence may leave the most vulnerable smokers with the most harmful product.
  

Communication

• The WHO is right to expose some language of commercial seduction.

• But public health also has a language problem of its own. When it refuses to distinguish nicotine from combustion, or lower-risk products from cigarettes, it produces confusion in the name of protection.

• And confusion favors the cigarette. When everything is made to sound equally dangerous, the most familiar product keeps its advantage.

The Strategic Question

The question is not: How do we stop nicotine pouches?

The better question is: Can public health prevent youth capture without denying harm reduction to smokers still exposed to combustion?

Recommended Actions

For Regulators & Public-Health Agencies

• Separate youth-prevention policy from adult harm-reduction policy.

• Regulate marketing, packaging, flavors, age access, nicotine strength, and product quality.

• Communicate clearly that lower risk does not mean risk-free.

• Monitor initiation, dual use, substitution, cessation attempts, and relapse separately.

• Stop treating all nicotine use as morally equivalent to smoking.

For Politics

• Do not use precaution as a substitute for proportionality.

• Keep combustion at the center of tobacco policy.

• Recognize that harm reduction is not surrender; it is a response to the limits of abstinence-only models.

• Ask whether restrictions reduce harm or preserve the cigarette’s dominance.

• Treat the nicotine policy as a question of inequality, evidence, markets, and risk, not only youth protection.

For Journalists & Opinion Leaders

• Avoid turning the report into a simple “new nicotine epidemic” story.

• Distinguish initiation, experimentation, dual use, substitution, and cessation.

• Keep adult smokers in the frame.

• Report marketing risks without collapsing all nicotine products into cigarettes.

• Explain the difference between nicotine, tobacco, and combustion.

The Risk of Misreading

This is not a defense of nicotine pouches as harmless products.

It is a critique of a public-health reflex: seeing every new nicotine technology primarily through the moral memory of the cigarette.

The WHO report is strongest when it exposes certain commercial tactics. It is weakest when it treats ambiguity as a regulatory inconvenience rather than as the central fact of the post-cigarette nicotine landscape.

Bottom Line

The WHO can see the danger of nicotine pouches as products of initiation. It still struggles to see their possible role as products of substitution. That is the unresolved public health problem after the cigarette.

Argentina has not simply legalized vapes. It has been admitted that prohibition no longer controls.

For more than a decade, electronic cigarettes were formally banned while circulating through kiosks, social media, informal deliveries, suitcases, school backpacks, and parallel markets. The law said absence. Daily life said coexistence.

ANMAT’s 2026 reversal, therefore, marks less a conversion to harm reduction than a bureaucratic recognition: the market had already arrived, grown, and escaped meaningful oversight.

The new regime brings electronic cigarettes, heated tobacco products, nicotine pouches, liquids, cartridges, and sticks into the legal sphere, but only under strict registration, traceability, taxation, flavor limits, health warnings, and state surveillance.

Argentina is not opening the market. It is trying to make it visible.

Why It Matters

The Argentine case exposes a basic policy failure: prohibition can survive legally while collapsing administratively. A ban may still exist on paper even after the state has lost the ability to inspect products, verify composition, prevent youth access, tax sales, or influence consumer behavior.

That is the real significance of the reform. Argentina is no longer regulating a future threat. It is trying to govern an accomplished fact.

The harder question is whether the new legal market will actually displace the informal one. If registered products become expensive, scarce, flavor-restricted, and surrounded by communication so cautious that adult smokers cannot understand relative risk, the reform may produce only a formal surface.

At the same time, the old gray market continues underneath it.

Evidence at a Glance

• Argentina banned electronic cigarettes in 2011, but the market continued to circulate informally.

• On May 4, 2026, ANMAT revoked the previous prohibition.

• The agency acknowledged that absolute bans can push consumers into informal and illegal circuits where products of unknown origin and composition circulate.

• Resolution 549/2026 created a Registry of Tobacco and Nicotine Products covering electronic devices, vape liquids, heated-tobacco products, sticks, and nicotine pouches.

• Disposable vapes remain banned; liquids and sticks may only use tobacco flavor; nicotine pouches may use tobacco or menthol.

• Decree 305/2026 increased import duties on several non-combustion nicotine products, bringing their tax burden closer to traditional tobacco.

• The Ministry of Health cited that 35.5% of adolescents had tried an electronic cigarette at least once — evidence that youth use had expanded before legalization, not because of it.

Why This Matters

Scientific

• The reform forces a distinction that much of Latin American public health still avoids: nicotine is not the same as combustion.

• No nicotine product is risk-free. Dependence, youth uptake, and product quality all matter. But treating every nicotine product as morally and scientifically equivalent protects the cigarette by default. For adult smokers, the relevant comparison is not vaping versus clean air. It is vaping versus continued smoking, informal products, or no realistic pathway away from combustion.

Regulatory

• Argentina is choosing a middle path: neither full consumer-market liberalization nor pharmacy-style medicalization.

• But the middle path is not automatically balanced. It can become a corridor so narrow that only large companies, expensive products, and highly controlled formats survive legally. The core test will not be the elegance of the decree. It will be enforcement: kiosks, e-commerce, parcels, borders, social networks, and sales to minors.

• The old mistake was believing prohibition meant control. The new mistake would be believing registration does.

Equity Implications

• Legalization does not guarantee access.

• Laboratory testing, registration, certification, traceability, import duties, and compliance costs favor large operators. Smaller importers, independent shops, and informal sellers may remain outside the legal market. Adult smokers, especially those with lower incomes, may face legal products that are more expensive, less varied, and harder to find than the informal alternatives already available.

• A harm-reduction pathway that exists only in regulation does not reduce harm. It must exist at the counter: affordable, available, understandable, and capable of competing with the cigarette.

Communication

• Argentina wants to legalize without appearing to endorse. That is politically understandable, but risky.

• If public messaging says only that “no product is risk-free,” without explaining comparative risk, adult smokers may hear equivalence. And when everything sounds equally dangerous, the cigarette keeps its advantage: familiarity.

• The state must prevent youth-oriented marketing without silencing information for adult smokers. Protection for minors and clarity for adults are not the same task.

The Strategic Question

The question is not: Are vapes safe?

The better question is: Can Argentina create a legal market restrictive enough to limit minors’ appeal, but accessible enough to help smokers move away from combustion?

Recommended Reflections and Actions

For Journalists & Opinion Leaders

• Do not describe the reform as simple legalization. It is legalization under surveillance.

• Keep the cigarette in the story: the most harmful product remains legal, familiar, and widely available.

• Follow the street, not only the Official Gazette: prices, shelves, kiosks, online sellers, parcels, borders, and school access.

• Avoid the false binary of “pro-vape” versus “anti-vape.” The real story is control, informality, youth protection, adult substitution, and relative risk.

For Regulators & Public-Health Agencies

• Build a registry that is fast, transparent, technically credible, and publicly accountable.

• Distinguish youth prevention from adult harm reduction.

• Monitor price, access, product availability, illicit-market persistence, and adult substitution away from cigarettes.

• Communicate relative risk clearly without turning products into lifestyle objects.

• Evaluate whether flavor restrictions reduce youth use or simply preserve the informal market.

For Politics

• Stop treating prohibition as proof of seriousness.

• Invest in the administrative capacity the reform requires: laboratories, inspectors, customs control, digital monitoring, and enforcement.

• Ask who the new compliance system favors: public health, consumers, large corporations, or the state’s need to appear in control.

• Measure success by outcomes, not decrees: less smoking, less illicit supply, less youth access, more traceability.

The Risk of Misreading

This is not a clean victory for harm reduction. Argentina has not fully embraced substitution, nor guaranteed meaningful access for adult smokers.

It is also not a meaningless bureaucratic shift. It ends a fiction: the idea that prohibition had kept vapes outside Argentine life.

The danger now is replacing one illusion with another, moving from pretending prohibition was control to pretending traceability is governability.

Bottom Line

Argentina has stopped pretending that prohibition worked. Now it must prove that regulation can do more than document what it still cannot control.

For deep reading:

The Core Tension

Smoking has declined, but not equally. The cigarette has retreated from offices, prestige culture, and public space, yet it has not disappeared from the lives of those most exposed to social and economic vulnerability.

The central tension is this: tobacco control often celebrates aggregate decline, while the remaining burden of smoking becomes increasingly concentrated among poorer and more precarious groups. What looks like public-health success at the population level may conceal a harder reality: harm has not vanished. It has moved down the social gradient.

The cigarette is no longer simply a habit, an addiction, or an individual choice. In many contexts, it has become a marker of class — not because smoking has changed in itself, but because its persistence now tracks the line between those able to move away from harm and those left closer to it.

Smoking has ceased to be socially diffuse and has become concentrated, which changes its political meaning .

Why It Matters

The decline of smoking is real. But treating that decline as a uniform victory is analytically lazy and politically dangerous.

It ignores the fact that those who continue to smoke are increasingly people whose lives are shaped by low income, precarious work, interrupted education, mental distress, weaker support networks, and irregular access to quit.

Public health often speaks of “the smoker” as if this were a neutral and universal category. It is not.

The term can erase the material conditions under which smoking persists. When campaigns rely mainly on warning, stigma, taxation, and individual responsibility, they assume that all people have the same capacity to respond. They do not.

Evidence at a Glance

A study by Sarah Jackson, Sharon Cox, Jamie Brown, and Vera Buss, published in Nicotine & Tobacco Research, used data from 2022 to 2024 for England, Scotland, and Wales.

Average consumption among smokers was estimated at 10.4 cigarettes per day, equivalent to 28.6 billion cigarettes per year.

Smoking prevalence was 18.8% in C2DE social grades, compared with 10% among higher-income groups.

Daily consumption was also higher among more vulnerable smokers: 11 cigarettes per day, compared with 9.4 among wealthier groups.

Annual per-capita consumption sharpened the inequality: 755 cigarettes among the most vulnerable groups, versus 343 among the wealthiest.

The central finding is not only that cigarettes are still consumed at scale, but that consumption is socially patterned. Harm is concentrated where vulnerability is already concentrated.

Why This Matters for Policy

Scientific

• Smoking should not be studied or discussed only as an aggregate behavior. The relevant question is no longer simply how many people smoke, but who continues to smoke, where, under what pressures, and with what realistic options for quitting or reducing risk.

• This requires a more stratified public-health lens. Class, income, geography, mental health, housing insecurity, education, race, gender, and access to care are not secondary variables. They are part of the conditions through which smoking persists.

• The scientific mistake is to treat behavior as detached from circumstance. The political mistake is to call that detachment neutrality.

Regulatory

• Policies designed for “the population” may fail when the burden has already become concentrated in a specific segment of society. Generic warnings, higher prices, denormalization campaigns, and punitive restrictions can produce unequal effects when applied to unequal lives.

• This does not mean abandoning tobacco control. It means making it more intelligent. Regulation should continue to reduce the appeal, availability, and harms of combustible tobacco, but it must also recognize that taxation and stigma alone cannot produce equal outcomes in unequal social conditions.

• A serious regulatory approach would ask not only whether a measure reduces smoking in aggregate, but whether it reduces the burden among those who are most exposed.

Equity Implications

• If smoking is increasingly concentrated among poorer and more vulnerable groups, then tobacco harm has become an equity issue. The remaining smokers are not merely people who failed to absorb public-health messaging. They are often people living under social conditions that make quitting harder, relapse more likely, and alternatives less accessible.

• Smoking now draws a border: not simply between smokers and non-smokers, but between those who were able to move away from harm and those who remained exposed to it.

• That matters because policies that treat unequal populations as if they were equal may look universal while functioning unjustly.

Communication

• Public-health communication still too often relies on moral simplicity: the responsible subject quits; the irresponsible subject persists. This framing may be rhetorically efficient, but it is socially crude.

• The language of individual responsibility can obscure the conditions that sustain smoking. It turns structural inequality into personal failure. It makes the smoker appear as someone who refuses correction, rather than someone whose options may be materially narrower.

• Journalists, advocates, and public-health institutions need to stop reproducing the abstract figure of “the smoker” without asking what kind of life that figure is being made to stand in for.

The Strategic Question

The strategic question is not: Why do people still smoke?

That question is too thin.

The better question is:

Who continues to smoke, under what pressures, in which social conditions, and with what real possibilities of escape?

Once the question changes, the policy horizon changes with it.

The issue is no longer only individual cessation. It becomes the unequal distribution of harm, and the failure of public policy when it treats unequal lives as if they were equally free.

Recommended actions

For regulators and public health agencies

• Stop designing tobacco policy around an abstract, universal “smoker.”

• Stratify smoking data by class, income, geography, mental health, housing, ethnicity, gender, and access to care.

• Evaluate tobacco control measures not only by the aggregate decline in prevalence, but also by their effect on the most exposed groups.

• Combine cessation support with mental health services, social support, and targeted community interventions.

• Treat harm reduction as an equity issue and not just a regulatory controversy.

• Avoid policies that intensify stigma without expanding realistic pathways away from combustible tobacco.

For Politics

• Stop using individual responsibility as a substitute for social policy.

• Recognize that smoking persists where other vulnerabilities accumulate.

• Address the harms of tobacco as part of a broader inequality agenda that involves poverty, housing, work, mental health, and access to care.

• Ask whether current policies reduce harm among the most vulnerable – or simply make smoking less visible to the most protected.

• Avoid the false comfort of universal policies that appear neutral but work unevenly.

For journalists and opinion leaders

• Avoid portraying remaining smokers as simply irrational, irresponsible, or ill-informed.

• Report the decline in smoking along with the concentration of smoking. Aggregate success without distributional analysis is incomplete.

• Ask who benefits from current political narratives and who disappears into them.

• Cover harm reduction without caricature: Lower-risk alternatives are not harmless, but blocking them can also have human costs.

• Replace the moral drama of “bad choices” with the more difficult story of unequal conditions, limited agency, and concentrated exposure.

The risk of misreading

This argument does not absolve the market. It does not romanticize smoking. It does not deny addiction, illness, or death.

The issue is clearer: a political mentality that reduces smoking to individual failure cannot explain why smoking declines most quickly among the protected and persists where life is most precarious. It also fails to explain why moral pressure alone cannot reach those who live under the harshest restrictions.

The danger is not that tobacco control becomes too serious about smoking. The danger is that it remains serious in the wrong way: morally severe, socially blind, and insufficiently attentive to the unequal distribution of harm.

Bottom Line

Smoking no longer describes society as a whole. Reveals where protection ends.

The Core Tension

• The combustible cigarette remains legal, visible, and widely available.

• Lower-risk nicotine products — vapes, snus, nicotine pouches, heated tobacco — are often treated with greater suspicion than cigarettes.

• Since 2014, the Global Forum on Nicotine has served as one of the main spaces where this contradiction is openly examined.

• The central dispute is not only scientific, but moral, regulatory, economic, political, and communicational.

• The 2026 theme, Prohibition and Public Health, returns to the unresolved question: what is public health protecting when the deadliest product remains available while less harmful alternatives are restricted?

Why It Matters

The debate over nicotine is often presented as a conflict between public health and industry. But the deeper question is whether public health can still distinguish between products, risks, contexts, and people. When all nicotine use is morally collapsed into the cigarette, policy loses the ability to reduce harm where abstinence has failed.

The GFN matters because it forces a difficult question into public view: if millions continue to smoke, and if noncombustible alternatives carry lower levels of risk, then prohibition is not automatically protective. It may become a way of preserving the cigarette’s dominance under the language of caution.

Evidence at a Glance

• 2014: GFN begins in Warsaw around the distinction between nicotine, dependence, combustion, and death.

• 2015–2017: The Forum shifts from endgame rhetoric to harm reduction, accountability, technology, and consumer inclusion.

• 2018–2019: The debate expands from toxicology to language, perception, compassion, and the moral imagination of public health.

• 2020–2022: Pandemic-era digital expansion turns GFN into a broader platform for mediation, archiving, translation, and public debate.

• 2023–2025: The Forum becomes less peripheral, confronting the interpretation of evidence, economics, communication, misinformation, and political resistance.

• 2026: “Prohibition and Public Health” crystallizes the paradox: why prohibit lower-risk alternatives while cigarettes remain legal?

Why This Matters for Policy

Scientific

• Public-health language often merges nicotine, tobacco, combustion, and harm into one moral category.

• Harm reduction depends on distinguishing dependence from the main drivers of smoking-related disease.

• Evidence must be interpreted by product type, use pattern, exposure, and population — not by symbolic association with smoking.

Regulatory

• Bans on lower-risk products can unintentionally protect the combustible cigarette.

• Regulation should differentiate risk instead of treating all nicotine products as equivalent.

• Overly restrictive rules may push consumers toward informal markets or back to cigarettes.

Equity Implications

• Smoking is concentrated among populations marked by inequality, dependence, precarious access to care, and misinformation.

• Policies built around ideal behavior often fail people who cannot or will not quit immediately.

• Harm reduction becomes an equity question when safer alternatives are available only to the informed, wealthy, or legally protected.

Communication

• The conflict is no longer only about what science shows.

• It is about what journalism, institutions, platforms, and public-health messaging allow society to hear.

• Miscommunication can become regulation by other means.

The Strategic Question

The question is not whether every nicotine alternative should be celebrated. The question is whether public health can regulate according to real differences in risk, or whether moral discomfort will continue to produce policies that leave the cigarette structurally protected.

Recommended Actions

For Regulators & Public-Health Agencies

• Regulate nicotine products according to relative risk.

• Separate youth-protection policy from adult smoking-cessation policy.

• Preserve access to lower-risk alternatives while controlling marketing, quality, labeling, and age restrictions.

• Treat prohibition as an intervention with consequences, not as a moral default.

For Politics

• Stop using “protecting public health” as a substitute for measurable outcomes.

• Ask whether bans reduce smoking or simply reorganize the market.

• Include consumers, clinicians, researchers, and affected communities in policy design.

For Journalists & Opinion Leaders

• Avoid collapsing vaping, heated tobacco, pouches, snus, nicotine, and cigarettes into one category.

• Report conflicts of interest without using them as a shortcut to avoid evidence.

• Cover both risks: youth uptake and adult smokers being denied lower-risk options.

The Risk of Misreading

• Harm reduction is not deregulation.

• Lower risk does not mean harmless.

• Industry involvement does not necessarily create real conflicts of interest.

• Youth protection remains necessary.

But none of these facts eliminates the central problem: cigarettes kill through combustion, and policies that obscure that distinction may preserve harm.

Bottom Line

Warsaw keeps asking the question public health keeps postponing: what is being protected when the cigarette survives, and its alternatives are treated as the greater threat?

A significant portion of preclinical exposure studies using high-powered, low-resistance (sub-ohm) devices operate under airflow regimes inappropriate for this device class. As a result, they frequently generate overheated, failure-mode aerosols that do not reflect routine human use.

Evidence at a Glance

• Common laboratory regimen: 3-second puffs, 55 mL, every 30 seconds (CORESTA CRM81/RM81-like), equivalent to ~1.1 L/min airflow.

• Engineering requirement: For sub-ohm devices, airflow closer to ~10 L/min is needed to prevent coil overheating.

• Observed outputs: Elevated aldehydes and, in some cases, carbon monoxide—signals consistent with thermal failure, not typical vaping.

• Scope: The paper evaluates methodological validity, not clinical efficacy or safety.

Why This Matters for Policy

Scientific Validity

If the experimental agent is an aerosol, then invalid aerosol generation invalidates downstream risk inference. Toxicology built on failure modes cannot be generalized to real-world exposure.

Regulatory Integrity

When laboratory-induced artifacts are treated as “typical vaping,” regulatory risk is shaped by invalid proxies rather than by representative evidence.

Equity Implications

Mischaracterizing alternatives to smoking disproportionately affects populations already bearing the highest burden of combustible tobacco use—those with fewer resources, fewer cessation options, and higher baseline risk.

Policy Implications

1. Evidence weighting must account for the validity of aerosol generation, not toxic endpoints alone.

2. Failure modes should not be silently generalized to standard exposure conditions.

3. Methodological shortcuts carry human costs by reinforcing policies that may prolong smoking rather than reduce harm.

Recommended Actions

For Regulators & Public-Health Agencies

• Require exposure studies to report:

  • Delivered (measured) power at the coil

  • Airflow rates

  • Device and coil specifications

  • Operational regime (optimal vs. overheating)

• Explicitly distinguish extreme or failure conditions from representative use in risk assessment.

For Journals & Research Funders

• Tighten reporting standards and checklists to reduce irreproducible or engineering-invalid exposure studies.

• Prioritize replication studies that map airflow × power × resistance to valid vs. overheating zones.

For Standards Bodies & Laboratories

• Develop device-class–specific protocols (pods ≠ sub-ohm).

• Implement pre-calibration workflows to prevent “screen watts” from substituting for delivered watts.

For Journalists & Opinion Leaders

• Interrogate methods before amplifying results

  When reporting on vaping studies, explicitly ask how the aerosol was generated: airflow, delivered power, device class, and operating regime. Toxicological findings without methodological context are not facts—they are poorly grounded claims.

• Avoid generalizing failure scenarios as typical of use

  Aerosols produced under extreme or overheating conditions should not be described as representative of everyday vaping. When studies probe limits or failure modes, this distinction must be made explicit to audiences.

• Distinguish plausible risk from manufactured risk

  Not every alarming result reflects a real-world exposure. Responsible science journalism does not elevate experimental artifacts into population-level conclusions.

• Contextualize social and distributive consequences
  Frames that collapse all alternatives to combustible smoking into a single risk category obscure who bears the cost of oversimplification: populations with higher smoking prevalence, fewer cessation options, and greater structural vulnerability.

• Resist moral certainty where technical uncertainty persists

  When methods are contested or incomplete, journalism should clarify limits—not replace them with moralized conclusions. Explaining uncertainty is not a weakness; it is a public service.

Bottom Line

A toxicological result is only as credible as the aerosol that produced it.
When laboratory protocols turn thermal failure into “evidence,” policy inherits the error—and vulnerable populations pay the price.

For Further Reading:

by John Keene

Love everything
Love the sky and sea, trees and rivers,
mountains and abysses.
Love animals, and not just because you are one.
Love your parents and your children,
even if you have none.
Love your spouse or partner,
no matter what either word means to you.
Love until you create a cavern in your loving,
until it seethes like a volcano.
Love everytime.
Love your enemies.
Love the enemies of your enemies.
Love those whose very idea of love is hate.
Love the liars and the fakes.
Love the tattletales and the hypercrits, the hucksters and the traitors.
Love the thieves because everyone has thought
of stealing something at least once.
Love the rich who live only to empty
your purse or wallet.
Love the poverty of your empty coin purse or wallet.
Love your piss and sweat and shit.
Love your and others’ chatter and its proof of the expansiveness
of nothingness.
Love your shadows and their silent censure.
Love your fears, yesterday’s and tomorrow’s.
Love your yesterdays and tomorrows.
Love your beginning and your end.
Love the fact that your end is another beginning,
or could be, for someone else.
Love yourself, but not too much
that you cannot love everything and everyone else.
Love everywhere.
Love in the absence of love.
Love the monsters breeding
in every corner of the city and suburb,
all throughout the soil of the countryside.
Love the monster breeding inside you and slaughter him
with love.
Love the shipwreck of your body, your mind’s
salted garden.
Love love.

Sometimes, the only honest way to survive is to sing hard, “as hard as life itself.”

That is the pulse running through Punks: New & Selected Poems, by John Keene: a book that refuses neutrality, that chooses combustion over contemplation, that turns archive into movement. It doesn’t merely gather decades of writing: it restages them as a living, insurgent, plural body.

Keene had already signaled his power in Annotations and Counternarratives. But it is in Punks that his voice reaches a turning point: more than an author, he emerges here as an archivist of the unnamable, a cartographer of what official history chose to forget — and what poetry, when sharpened, dares to remember.

With each page, the language shifts, as if shedding skin.

Form here is not ornament; it is a tool, it is a blade, it is music.

And what does it cut?

Silencing. Erasure. The comfort of fixed categories.

Keene summons an unruly chorus of Black presences, intimate and historical: bodies in bars, in bedrooms, in emotional trenches. These are voices that sing mourning without losing the rhythm of joy, that traverse AIDS and oppression with the same breath that claims love and desire. They are lovers, friends, ghosts. And no one here asks permission to fit into a single narrative.

There is, in fact, something of the ethics of harm reduction in this book: a radical listening to forms of life that endure even when wounded, that create beauty even when marginalized. Lives not seeking moral cure, but dignity and continuity.

Poetry here becomes, in many ways, a form of care. Not a care that domesticates, but a care that acknowledges the wound without trying to erase it, violate it, or silence it; it directs love toward the wound that holds pain and desire as inseparable facets of survival.

This is not a book about identity. It is a work that acts upon identity. That unsettles it. That insists: poetry doesn’t need to explain itself, it needs to exist. With thickness. With contradiction. With desire.

Punks does not describe history. It keeps it raw. And in doing so, it transforms it, as if wrapping it in a skin that is both resistant and radiant.

If I could, this would be the Christmas gift I’d give each of you.

Merry Christmas.

• Comparative policy analysis across nine national jurisdictions (Austria, Bulgaria, Canada, Ecuador, France, Israel, Luxembourg, Pakistan, Russia, Switzerland) investigates how nicotine alternatives are regulated as a single moral category rather than by risk profile.

• Concrete signals of “prohibition-by-design”: Luxembourg’s 0.048 mg nicotine-per-unit cap (effective 01/01/2026), Pakistan’s 40 mg/ml nicotine cap and 50m school buffer, Israel’s proposed 1-shekel/ml tax plus 30-shekel/device charge, and Russia’s pathway toward public-space bans and a proposed broader ban.

• Economic architecture tells the story: Austria’s monopoly and licensing system, Israel’s secret taxation and reporting rules, France’s (temporary) refusal to implement an excise or online ban, Canada’s retroactive liability expansion, each one reshapes markets, incentives, and access points.

• Cost-effectiveness logic is implicitly inverted: instead of pricing and regulating to accelerate the transition away from combustion, multiple regimes flatten differences, increasing the likelihood of market retreat to cigarettes or expansion of illicit/grey supply.

• Equity implications are inhumane: when safer alternatives are dismissed as equally invalid, the first to lose access are those who need them most: adult smokers with fewer resources, less clinical support, and less political visibility.

Why It Matters

This text describes the quiet pattern that mainstream tobacco control rhetoric continues to promote: we are not observing the evolution of “public health policy”; we are witnessing a moral reflex becoming standardized across borders. 

The convergence isn’t a conspiracy; it’s worse. It’s administrative mimicry: the same set of bans, caps, invisibility tactics, distribution choke points, and financial penalties, copied across legal cultures because it is easy to implement and difficult to challenge.

The scandal isn’t that governments regulate nicotine alternatives; it’s that they treat smoke and vapor as the same thing, as if combustion were just a “delivery method” and not the main cause of death.

When you remove nuances, you remove strategy. And without a plan, the focus is only on policing: markets, visibility, desire, or the chance that people might switch rather than give up. Public health becomes a costume; the human body becomes the stagehand crushed when the set changes.

What Changes in Practice

Health/Regulation – Equivalence regimes displace risk-proportionate regulation: the same prohibitions, advertising erasures, and access bottlenecks are applied to products with radically different harm profiles, often without transparent publication of the underlying legal text (Israel) or without empirical modeling (Russia).

Industry/Innovation – The incentive structure tilts toward incumbency: cigarettes remain legible, taxable, and politically “tamed.” At the same time, alternatives face monopoly capture (Austria), viability-killing thresholds (Luxembourg), and litigation risk that chills the category itself (Canada). Innovation becomes irrational when the legal system treats substitution as wrongdoing.

Society/Environment – A new form of censorship is emerging: not of speech, but of availability and appearance. Switzerland’s emphasis on making marketing “invisible,” Bulgaria’s sensory erasures, and France’s paused restrictions reveal the same battleground: who may occupy public space and which choices are permitted to be seen.

Scenarios and Next Steps

Short term (1–2 years): Rapid spread of copy-paste restrictions (caps, flavor/sensory bans, online-sales bans), plus stealth regulation via taxation and licensing. Expect friction to push some demand into informal markets, especially where enforcement capacity is weak but moral certainty is high.

Medium term (3–5 years): A measurable divergence emerges: jurisdictions that preserve access pathways for adult switching will likely see faster declines in combustible use; jurisdictions that restrict substitution will see cigarette persistence, along with the proliferation of unregulated alternatives. Litigation and monopoly models will concentrate markets and narrow consumer choice.

Long term (5–10 years): Two public-health ideologies harden into infrastructure:

1. A regime that treats harm reduction as heresy and governs nicotine through disappearance, and

2. A minority regime that accepts degrees, builds transition pathways, and makes cessation and switching compatible rather than mutually exclusive.

The Takeaway

When the state refuses to consider graduations, it doesn’t prevent harm: it shields the cigarette by making the exits illegal, invisible, or economically unfeasible.

For Further Reading:

The Essentials

• By Gabriel Oke, observational political analysis of COP11 (WHO Framework Convention on Tobacco Control), held in Geneva in Nov 2025, with focus on African delegations and negotiations under Articles 18, 19, and 2.1.
  

• Key outcomes: no global ban on filters or e-devices; Article 19 strengthens pathways for legal accountability but without mandatory levies; Article 2.1 endgame measures remain voluntary.
  

• Economic pressures remain acute: countries must regulate device waste and disposables, and address litigation pathways, largely without new external financing.
  

• Cost-effectiveness hinges on flexible regulation, risk-proportionate strategies, and the development of domestic legal capacity rather than adopting one-size-fits-all global bans.
  

• Implications for inequality: exclusion of African civil society, fragile waste systems, and limited cessation services highlight persistent asymmetries in global health governance.
  
  

Why It Matters

COP11 exposed a long-standing fracture: a global treaty built for a world of cigarettes is struggling to govern a landscape of new nicotine technologies and uneven state capacity.

Africa enters the debate not as a peripheral actor but as the region where tobacco harms remain highest, cessation infrastructure remains weakest, and economic and logistical realities most constrain regulatory experimentation.

The Geneva session revealed a shift in tone: African negotiators pushed back against prohibitionist reflexes, insisted on feasibility, and challenged the exclusion of local voices.

Behind the diplomatic language lies a more profound political truth: no global treaty can claim legitimacy while making decisions for a billion Africans who are not in the room. Evidence, not dogma, must shape the path ahead.

Ultimately, beyond the technicalities of filters, waste streams, and litigation frameworks, COP11 illuminated something more human: the fight for agency.

Africa is no longer asking to be heard. It is asserting the right to shape its own health future.

What Changes in Practice

Health/Regulation – Countries must design realistic regulations for disposable vapes, e-device waste, and filters, without a global mandate or new funding.
Endgame measures remain voluntary, giving flexibility but no guarantee of progress. Legal frameworks must evolve to enable effective use of Article 19.

Industry/Innovation – Regulatory uncertainty delays investment in safer alternatives and waste-management innovations. Flexible, risk-proportionate pathways could incentivize technologies that lower harm and reduce environmental burdens.

Society/Environment – Waste systems already strained in many African nations face new responsibilities. Exclusion of civil society deepens mistrust and widens representation gaps, affecting farmers, consumers, and researchers.

Scenarios and Next Steps

Short term (1–2 years): Countries assess waste-management capacity; begin drafting national legal strategies under Article 19; map cessation gaps; initiate consultations with civil society excluded from COP.

Medium term (3–5 years): Development of integrated regulatory systems for new nicotine products; establishment of specialized legal units for litigation against transnational tobacco corporations; pilot harm-reduction programs where relevant.

Long term (5–10 years): Strengthened public health systems capable of regulating across the risk spectrum; continent-wide collaboration on legal and environmental strategies; Africa increasingly shaping—not receiving—global tobacco policy doctrine.

The Takeaway

“A warning shot was fired in Geneva: Africa will no longer inherit a tobacco future designed elsewhere.”

For Further Reading:

• Policy analysis of late-2025 nicotine regulation across Europe, Latin America, and Asia, mapping a de facto “natural experiment” in prohibition vs. regulation.

• Converging pattern: combustible cigarettes remain legal and readily available, while lower-risk alternatives (vapes, pouches, heated products) face bans, fiscal penalties, or severe sales restrictions.

• Economic effects include consolidation of cigarette oligopolies, expansion of grey and illicit markets, and tax designs that risk pushing consumers back toward cheaper, more harmful combustible products.

• Policies systematically ignore risk-proportionate regulation, undercutting the cost-effectiveness of harm-reduction strategies that could reduce healthcare burdens from smoking-related disease.

• The burden falls hardest on adult smokers, especially poorer and marginalized groups, who are left with full-risk cigarettes or unregulated markets, while “protecting children” becomes the dominant, unexamined political shield.

Why It Matters

This piece exposes how the new global “war on nicotine” confuses the molecule with the method of delivery.

From Brussels to Buenos Aires, governments invoke "kids” to justify bans and restrictions that leave the most lethal product, combustible cigarettes, intact, while pushing safer alternatives into legal limbo or outright illegality.

Public health language is deployed, but the practical result is a regulatory map that makes it easier to buy what kills most people than what could reduce harm.

Behind the legal symmetry lies a social asymmetry.

People who already smoke, often poorer, more precarious, and less visible to policy-makers, lose access to regulated, lower-risk options and are pushed either back to cigarettes or into informal markets without age checks, product standards, or accountability.

The article reminds us that this is not just a debate about devices and decrees, but about which bodies are allowed a safer exit from dependence, and which are quietly written off.

What Changes in Practice

Health/Regulation –

• Ministries and regulators are choosing prohibitionist shortcuts: bans, generational prohibitions, blanket equivalence between products rather than the more complex work of risk-based regulation, cessation support, and structured harm-reduction pathways.

• The WHO FCTC framework, as interpreted in recent decisions, is reinforcing a “one-size-fits-all” model that blurs the risk gradient and sidelines harm reduction as a legitimate public health tool.

• Countries like Portugal and Argentina, which tentatively regulate nicotine pouches and vapes instead of pretending they don’t exist, outline an alternative: acknowledge reality, regulate it proportionally, and protect minors without abandoning adults.

Industry/Innovation –

• Fiscal and legal architectures in France, Mongolia, South Korea, Mexico, and Uzbekistan tend to protect incumbent cigarette markets while suffocating or criminalizing lower-risk products, distorting incentives away from innovation in harm reduction.

• Regulatory overreach (e.g., flavor bans, online sales bans, treating synthetic nicotine as “tobacco”) encourages a shift of supply toward grey and illicit channels where science, standards, and traceability vanish.

• Companies developing non-combustible products face fragmented, hostile environments; only where regulation recognizes risk differentials can genuine transitions away from combustion be commercially viable.

Society/Environment –

• “Protect the children” rhetoric homogenizes risk and erases adults who smoke from the moral field, deepening stigma and narrowing political imagination around care for long-term users.

• Environmental arguments (e.g., single-use vapes in Ireland) are treated in isolation, disconnected from broader nicotine policy, leading to measures that may reduce visible waste while increasing hidden health harms.

• The social contract around nicotine is being rewritten from above, with closed-door diplomatic rituals and technical language masking decisions that will shape everyday life in poor neighborhoods, informal economies, and overstretched health systems.

Scenarios and Next Steps

Short term (1–2 years):

• Rapid spread of copy-and-paste measures: flavor bans, online-sales bans, taxes that treat all nicotine products as equivalent, and new constitutional or criminal prohibitions on vaping and related devices.

• Growth of informal and illicit markets in countries pursuing absolute bans (Mexico, Uzbekistan, Turkey), with enforcement focused on supply rather than on providing safer exits for people who smoke.

• Initial implementation of outlier experiments. Portugal’s tax category for pouches and the UK’s inserts with cessation information are small but significant cracks in the abstinence-only paradigm.

Medium term (3–5 years):

• Divergence between jurisdictions that double down on prohibition and those that move toward risk-proportionate regulation, generating contrasting trends in smoking prevalence, illicit trade, and health-system costs.

• Accumulation of empirical data showing whether bans on disposables, flavor restrictions, and generational prohibitions reduce smoking, or merely shift use to cigarettes and unregulated markets.

• Pressure from clinicians, consumer groups, and some regulators to reopen the harm-reduction debate inside WHO processes and regional blocs, using evidence from countries that chose regulated alternatives.

Long term (5–10 years):

• Structural entrenchment of two models: one that criminalizes safer alternatives while preserving the cigarette, and another, a minority model that integrates harm reduction into mainstream tobacco control.

• Cultural shifts in how nicotine is perceived: either as an undifferentiated “threat” that justifies permanent prohibition, or as a complex dependency that can be managed with tools calibrated to real-world risk.

• Population-level outcomes diverge: where risk-proportionate policies prevail, smoking-related morbidity and mortality fall faster; where superstition is written into law, the burden remains concentrated among the most vulnerable.

The Takeaway

A health policy that makes it easier to buy cigarettes than their safer alternatives is not protecting the future; it is legislating denial and calling it care.

For Further Reading:

A parallel, multi-day conference (“Good COP”) held a few minutes from the official COP11, convening scientists, clinicians, users, advocates, and policy experts from multiple regions to debate tobacco harm reduction and global nicotine regulation.

The agenda is structured around high-stakes panels on Article 2.1 of the FCTC, “THR in the Americas,” the Swedish experience, philanthro-colonialism, EU TPD/TED review, and user agency, shifting the focus from slogans to empirically grounded, risk-proportionate policies.

Economic and funding dynamics are explicitly brought to the center: affordability and access in LMICs, costs of prohibitionist approaches, illicit markets, and the role of conditioned funding and large philanthropy in shaping what becomes “possible” policy.

The gathering serves as an impact intervention rather than a side event, dissecting regulatory capture, semantic manipulation, and opaque treaty mechanisms while advocating for models of regulation based on informed consent, reduced risk, and measurable health benefits.

Voices from the Global South, Eastern Europe, and organized user groups confront the democratic deficit in tobacco control, contesting the notion of “policy without us” and demanding co-authorship of norms that currently treat them as objects of regulation rather than political subjects.

Why It Matters

The Good COP reframes tobacco control not as a closed, technocratic ritual, but as a contested political space in which those who bear the consequences demand the right to speak and be heard in the language of evidence.

By placing ex-smokers, organized users, and researchers from the Philippines, Thailand, Nigeria, Costa Rica, South America, and Southeast Asia alongside long-time public health figures, it challenges the idea that “science” only flows from Geneva, Brussels, or Washington.

At stake is more than nicotine. The conference highlights how moralistic, prohibition-driven regulation can exacerbate inequalities, criminalize poverty, and impose one-size-fits-all policies in fragile contexts where law enforcement already poses a source of harm.

By interrogating Article 2.1, philanthro-colonialism, and the erasure of user voices, the Good COP insists on a different principle: that public health without democratic agency is not protection, but administration. It reminds us that behind every spreadsheet and clause, there is breath. And breath is never neutral.

What Changes in Practice

Health/Regulation – The Good COP advocates for regulatory frameworks that prioritize combustion reduction, rather than abstinence at any cost. This includes differential regulation for low-risk products, protection of access to less harmful alternatives, and sunset clauses for policies that generate more harm than they prevent.

It also proposes a re-reading of the FCTC—especially Article 2.1—as a tool for national autonomy instead of a backdoor for soft mandates and coercive “guidance.”

Industry/Innovation – By treating devices like Sweden’s Stingfree/PROTEX as both technical solutions and political allegories, the event signals that innovation should be judged by risk and benefit, not by moral panic or origin.

It opens up space for partnerships in which independent science, user communities, and responsible manufacturers co-produce standards of safety, transparency, and accountability, rather than being locked into an adversarial caricature.

Society/Environment – User testimonies from Africa, Asia, and Latin America reframe harm reduction as a question of dignity and survival in economies where prohibition feeds illicit markets and policy violence.

The Good COP suggests that “participation” means more than being surveyed: it means letting those who live under the rules help write them.

This has cultural implications that extend beyond nicotine, affecting how global health institutions interact with the people they claim to serve.

Scenarios and Next Steps

Short term (1–2 years): Replication of Good COP–style parallel forums at future COP meetings and other UN gatherings, building a documented “living record” of dissenting science and user testimony.

Strengthening of transnational networks linking researchers (e.g., Canada, Mexico, Greece, Malaysia, Sweden) and organized users (The Coalition of Asia Pacific Tobacco Harm Reduction Advocates, Africa Harm Reduction Alliance, ARDT Iberoamérica, advocates from Eastern European countries) around concrete demands: open sessions, transparency in funding, and explicit recognition of harm reduction within FCTC implementation.

Medium term (3–5 years): Incorporation of risk-proportionate regulation into national tobacco control strategies in a growing number of countries, particularly where illicit markets and enforcement-driven policies have visibly failed. Emergence of alternative guidelines and model laws, authored by mixed coalitions of scientists, users, and local policymakers, that compete with, or complement, WHO and PAHO templates, especially in the Global South.

Long term (5–10 years): Gradual cultural shift away from prohibitionist reflexes toward a public health paradigm that treats adults as agents, not targets.

If the Good COP’s agenda gains traction, we can expect structural changes: a reduced burden of smoking-related disease through sustained decline in smoking, diminished space for philanthro-colonial influence over domestic priorities, and a new norm where no major health policy is drafted “about” people without their organized participation.

The Takeaway

When official policy is written behind closed doors, a parallel conference can reopen a window, allowing those who bear the consequences to help write the rules.

• Good COP – full agenda (PDF):
  https://www.protectingtaxpayers.org/wp-content/uploads/2025/11/Media-Fin-2.0-Updated-agenda-2.pdf

• Good COP livestreams (YouTube): https://www.youtube.com/@ProtectingTaxpayers/streams

For Further Reading

• Expert clinical interview synthesizing RCTs, Cochrane reviews, and practice-based evidence on adult smokers; focus on cessation versus tobacco harm reduction (THR).
  

• Conventional therapies: ~8% quit at 6 months with nicotine patches and ~14% with varenicline; only ~6% remain abstinent at 4 years in trials; nicotine vaping is ≈59% more effective than standard NRT; two in three smokers die prematurely if they continue.
  

• Economic lens: THR can reduce healthcare costs by preventing smoking-related disease and by enabling relapse prevention; affordability and access to safer nicotine are critical.
  

• Impact: Offering a spectrum of safer nicotine products (vapes, heated tobacco, pouches, snus) alongside meds and counseling likely increases quits and reduces relapse—high value for money even when long-term nicotine use is needed.
  

• Equity & policy: Vulnerable groups have lower cessation rates; stigma and misinformation about nicotine block access. Training clinicians and regulating for availability, quality, and fair pricing are essential to narrow health gaps.

Why It Matters

• After decades of effort, abstinence-only strategies deliver modest, fragile outcomes. Most people who smoke will try—and fail—many times, often without tailored support or practical tools for relapse prevention.
  
  THR reframes the goal: reduce harm now, even if nicotine continues, by replacing combustion with far safer delivery.
  

• This matters for equity. People in precarious conditions face more triggers, less time, and fewer services. Expanding options—while correcting myths about nicotine—aligns clinical care with real lives, not ideal scenarios.
  
  Numbers tell one story; dignity tells another: not everyone wants to quit nicotine, but everyone deserves a safer option.

What Changes in Practice

• Health/Regulation – Integrate THR into clinical guidelines; authorize regulated access to quality-assured vapes, pouches, snus, and heated tobacco; scale brief interventions plus follow-up; fund clinician training on dosing, device selection, and relapse prevention; adopt clear, stigma-free language (“dependence” vs. “addiction”).
  

• Industry/Innovation – Incentivize safer-by-design products, nicotine titration ranges, and open systems that enable stepped reductions; enforce product standards, toxicology transparency, and youth safeguards; support pharmacovigilance and real-world effectiveness studies.
  

• Society/Environment – Public campaigns to debunk nicotine myths; prioritize outreach for high-risk groups; smoke-free norms paired with harm-reduction access; reduce tobacco-smoke pollution by accelerating substitution away from combustion.

  ---

Scenarios and Next Steps

• Short term (1–2 years): Update cessation protocols to include THR; train clinicians on combined therapies (e.g., patch + fast-acting NRT; or meds + vaping); ensure affordable access; create decision aids for shared choice; set up proactive follow-up during the first month post-quit.
  

• Medium term (3–5 years): Integrate THR into national tobacco-control strategies; reimbursement for safer nicotine products and counseling; standardize product quality and labeling; establish surveillance of quit and relapse outcomes across modalities.
  

• Long term (5–10 years): Structural decline in smoking prevalence; cultural shift from abstinence-only to patient-centered risk minimization; measurable reductions in cardiopulmonary morbidity and mortality; narrowed inequalities through equitable access to safer nicotine.

The Takeaway

A pragmatic truth: when quitting combustion is the priority, safer nicotine isn’t the problem—it’s the path.

For Further Reading:

• Dr. Colin Mendelsohn’s website

• Stop Smoking Start Vaping e-book (free PDF copy)

• Stop Smoking Start Vaping paperback and e-book

This interview is part of the book Las Certezas Salvajes — Ensayo sobre la historia, la farmacología, los efectos y los imaginarios sistémicos de la nicotina (The Wild Certainties: Essay on the History, Pharmacology, Effects, and Systemic Imaginaries of Nicotine) and the e-book Além da Força de Vontade (Beyond Willpower).

~ Free EPUB download.

Source: World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use, 2000–2024 and Projections, 2025–2030 (6th ed., 2025).

The Essentials

• Global monitoring report synthesizing 2,034 national surveys covering 97% of the world’s population; trend analysis 2000–2024 with projections to 2030.

• Tobacco users fell from 1.38B (2000) to 1.2B (2024); ~120M fewer since 2010; still ~1 in 5 adults use tobacco. Regional highlights: men in South/Southeast Asia down 70% → 37%; Europe now highest regional prevalence (24.1%); global women 11% → 6.6%, men 41.4% → 32.5%.

• Economic stakes: shifting even 1% of smokers to cessation or non-combustibles saves thousands of lives and large healthcare costs; excise design must avoid illicit markets and fund cessation, surveillance, and education.

• Impact/cost-effectiveness: Cochrane reviews indicate nicotine e-cigs increase quit rates vs. NRT; real-world signals from Sweden/Japan suggest population-level harm reduction when non-combustibles displace smoke.

• Equity & policy: ~80% of users live in LMICs; Africa shows declining prevalence but rising absolute numbers; Europe’s female prevalence (17.4%) is the world’s highest—underscoring gender and regional inequities

Why It Matters

The report confirms a real win—less smoking—while exposing a harder truth: progress is uneven, language is political, and policy often lags behind evidence. The word “epidemic” is more political than technical. Calling smoking an “epidemic” mobilizes action, but when advocacy blurs prevalence with “addiction,” nuance—and people—get lost.

Public health works when it balances protection of youth, support for adults who smoke, and clarity about relative risks. Behind every percentage is a biography: a body that coughs in the morning and reaches for relief at night. Evidence must meet that body with proportion, not purity.

What Changes in Practice

Health/Regulation – Separate nicotine from smoke in all guidance; integrate e-cigs, pouches, heated tobacco, and NRT into stepped cessation for highly dependent adults; protect minors with strict age-gating, marketing limits, product standards; improve surveillance (daily vs. experimental use; cessation trajectories).

Industry/Innovation – Incentivize low-toxicant, non-combustible designs; mandate independent emissions testing, tamper-resistant packaging, and robust age verification; channel data-sharing to public registries to accelerate safety science.

Society/Environment – Treat determinants of health (income, housing, work, education, gender burden) as tobacco policy; invest tobacco tax revenue in free cessation, mental-health support, leisure/community spaces, and clear, non-moralistic education.

Scenarios and Next Steps

Short term (1–2 years): Update clinical pathways to include harm-reduction options; redesign excise to maintain the highest prices on combustibles and a clear differential for non-combustibles; enforce youth protections; upgrade surveys to capture use intensity and quit trajectories.

Medium term (3–5 years): Scale biomarker-based cessation programs; fund independent long-term studies (respiratory/cardiovascular endpoints) with open data; expand licensing and retailer audits; integrate determinants (cash transfers, housing, flexible work) into tobacco strategies.

Long term (5–10 years): Normalize “smoke-free nicotine” as cessation/maintenance for the hardest-to-quit; drive structural declines in combustion to rarity; close gender gaps in care; embed proportionate risk communication into school curricula and primary care.

The Takeaway

Winning means less fire, fewer coughs, protected kids—and policies sized to people, not ideals.

For Further Reading:

Share

The Essentials

• Regulatory critique of Spain’s proposed ban on vaping in open public spaces, treating it as equivalent to tobacco smoke.

• Key scientific studies show that passive exposure to vaping is minimal and chemically distinct from tobacco smoke.

• Vaping generates far fewer and less toxic particles than combustible cigarettes, especially in outdoor environments.

• No evidence supports the proportionality of outdoor vaping bans under harm reduction and public health frameworks.

• The policy reinforces stigma, moral panic, and symbolic denormalization rather than evidence-based health protection.

Why It Matters

Spain’s proposed ban on vaping in open spaces reflects a growing global trend: the conflation of nicotine with tobacco, and the substitution of moral symbolism for scientific evidence in public health policymaking.

What should be a measured, differentiated approach grounded in harm reduction is instead flattened into a binary prohibition.

Beyond the particles and studies, the issue touches the very heart of public health ethics: can we justify banning something not because it harms others, but because it unsettles cultural norms? To legislate against a vapor that vanishes in seconds is to prioritize appearance over impact—and to deny smokers one of the few effective tools to reduce harm.

What Changes in Practice

Health/Regulation – Spain’s public health strategy should realign with evidence-based frameworks, distinguishing between smoke and vapor. Harm reduction must be included as a pillar of tobacco control policy.

Industry/Innovation – Clear regulatory separation between combustible and non-combustible nicotine products would foster innovation in safer alternatives and support risk-proportionate communication to consumers.

Society/Environment – Outdoor vaping bans, under the guise of public hygiene, reinforce stigma and social exclusion, particularly targeting marginalized populations in transition away from smoking.

Scenarios and Next Steps

Short term (1–2 years): Urgent need for public debate, media literacy campaigns, and counter-narratives to challenge misinformation about vapor exposure and relative risks.

Medium term (3–5 years): Integration of harm reduction into national health policies; revision of laws conflating all nicotine use with tobacco smoking.

Long term (5–10 years): Structural shift in public perception of nicotine; restoration of scientific legitimacy in regulatory discourse; recognition of former smokers as allies in public health progress—not hygienic pariahs.

The Takeaway

A wisp of vapor, gone in seconds, should not carry the weight of punishment that dense tobacco smoke once did.

For Further Reading:

Source: Tobacco and stunting: WHO tobacco knowledge summaries

The Essentials

• A critical essay analyzing the WHO report “Tobacco and Stunting” focused on childhood growth delays and maternal smoking.

• Highlights methodological inconsistencies: while prenatal smoking is linked to fetal growth restriction, postnatal stunting remains scientifically uncertain.

• The report marginalizes structural causes such as poverty, sanitation, racism, and maternal stress—reducing a complex social tragedy to a behavioral issue.

• By omitting harm reduction and equating all nicotine products, the WHO sustains a prohibitionist dogma at the cost of pragmatic transitions.

• Ethical concerns: how public health narratives can moralize vulnerability, shift blame to poor mothers, and obscure systemic responsibility.

Why It Matters

This essay opens a window into how global health institutions, in pursuit of unified messages, may flatten complexity, erase context, and transform uncertainties into absolutes. The WHO’s report on tobacco and stunting shifts the center of attention from structural injustices—poverty, food insecurity, racism, gendered violence—toward a singular behavioral target: maternal smoking.

But what happens when scientific nuance is sacrificed in the name of clarity? When biopolitical discipline replaces care? The result is a public health policy that punishes those with the fewest choices: mothers smoking in refugee camps, children exposed to stoves burning anything that burns, and infants born in bodies too small for the futures they deserved.

This is not just a scientific critique—it is a moral indictment. Because in the ruins of simplification, lives get smaller. And the tape that should measure growth ends up measuring neglect.

What Changes in Practice

Health/Regulation – Global health institutions, including the WHO, must reorient their strategies to prioritize structural determinants—such as clean water, adequate food, sanitation, education, and housing—at the forefront of childhood health policies. Behavioral risks like smoking should be addressed, but without eclipsing the broader socio-economic landscape. Integrating harm reduction into global policy frameworks is not optional—it’s a matter of scientific integrity and ethical responsibility.

Industry/Innovation – Clarifying the risk differentials between nicotine products is not just a scientific necessity, but a moral imperative. This calls for a regulatory environment that supports rigorous, independent research and allows non-combustible nicotine alternatives to be evaluated—and potentially implemented—as viable harm reduction tools.

Society/Environment – Childhood stunting is not merely a biomedical outcome, but a historical and social one. Effective responses must incorporate intersectional strategies that take into account race, gender, class, and environmental injustice. Recognizing the colonial roots of inequality is a crucial first step toward designing public health policies that not only measure disparities but also actively dismantle them.

Scenarios and Next Steps

Short term (1–2 years):

• Public debate on the ethics of behavioral reductionism in global reports.

• Strategic inclusion of harm reduction language in WHO and partner documents.

• Pressure on institutions to clarify distinctions between nicotine products.

Medium term (3–5 years):

• Integration of social determinants of health into funding priorities and evaluation metrics.

• Development of public health communications that reflect uncertainty and complexity.

• Institutional support for hybrid strategies: structural + behavioral.

Long term (5–10 years):

• Cultural shift in global health from prohibitionist paradigms to contextual, equity-driven care.

• Rewriting of WHO narratives to include colonial legacies and lived experience.

• Measurable reduction in childhood stunting through multi-factorial, structural interventions.

The Takeaway

A cigarette may shrink a body—but poverty, violence, and erasure shrink a future.

For Further Reading:

Source: Frontiers in Public Health (2025); Acta Odontologica Scandinavica (2025)

The Essentials

• Cross-sectional survey in Riyadh with 813 adults, mapping awareness, experimentation, and symptoms related to nicotine pouches.

• 59.3% awareness, 14.2% lifetime use, with strong age and gender gaps; almost all users were smokers or former smokers (95.8%).

• The main reported adverse events were abdominal symptoms, but favorable perceptions predominated among users.

• Stockholm pilot study with 23 dentists using Stingfree® pouches showed a reduction in oral lesions from 95.7% to 69.6% and gingival irritation was reduced by 90%.

• Evidence suggests that harm reduction potential exists if substitution occurs, but emphasizes the need for regulation, equity, and monitoring to prevent unintended health inequalities.

Why It Matters

These studies illustrate how a discreet white pouch—no smoke, no ash—sits at the intersection of public health, culture, and technology. In Saudi Arabia, nicotine pouches circulate quietly among young men, signaling both curiosity and uncertainty in a society where regulation lags behind practice. In Sweden, a family-born invention validated by academics shows that a minimal and creative design tweak can reduce gum irritation, hinting at how engineering can translate into health gains.

Together, they reveal the same paradox: nicotine is ancient, but the ways societies negotiate its risks and meanings are ever new. The challenge is not only scientific but ethical—can health systems transform data into care, ensuring that safer alternatives reach those who need them most, rather than letting the market alone dictate trajectories? Beyond statistics, these studies echo a simple human demand: less suffering, more dignity.

What Changes in Practice

Health/Regulation – Regulators must decide whether to treat nicotine pouches as an ally in harm reduction or a threat to abstinence-driven models, and prevent black markets or inequitable access.

Industry/Innovation – Small-scale, user-driven inventions (such as Protex®) can shift the harm-reduction landscape. Strategic partnerships between independent innovators and academic institutions can accelerate the development of safer products.

Society/Environment – Cultural contexts redefine meanings: in Riyadh, nicotine pouches symbolize modernity; in Stockholm, continuity. Both settings underscore that public health must engage with lived practices, not just abstract risks.

Scenarios and Next Steps

Short term (1–2 years): Expansion of pilot trials, regulatory monitoring in Saudi Arabia, and broader dissemination of clinical safety data.

Medium term (3–5 years): Integration of pouch products into harm reduction policies; comparative studies with other nicotine delivery systems; stronger educational campaigns.

Long term (5–10 years): Cultural normalization of low-risk nicotine alternatives, potential reduction in smoking-related morbidity and mortality, and shifts in how societies conceptualize nicotine itself.

The Takeaway

A tiny membrane inside a quiet pouch beneath the lip can redraw the map of nicotine, transforming smoke into breath, stigma into discretion, harm into health possibility.

For Further Reading:

The essay shows that what collapses is not only budgets but the very imagination that once sustained solidarity. Vertical campaigns may save lives in the short term, but they hollow out the systems meant to endure. Numbers dazzle, yet the most fragile are left unprotected. The pandemic tore away the last illusions: health was traded as an asset, while debts multiplied.

To reclaim health as a language of solidarity is not nostalgia but survival — because beyond graphs, there are bodies. And politics decides who breathes.

The Essentials

• Type & scope: Historical-analytical essay on the turning point in global health — from the universalist utopia (Alma-Ata) to today’s philanthrocapitalism, dependency, and multilateral retreat.

• Main findings: Collapse of the “implicit pact” that sustained global health in the 1990s–2010s; stagnant/volatile funding; systems fragmented by vertical campaigns; rise of regional blocs (e.g., Africa CDC) and China’s expanding Health Silk Road.

• Costs & economy: Post-COVID revealed sovereign debt burdens and conditionalities; short-term gains (high-impact campaigns) coexisted with chronic underinvestment in systems, workforce, and primary care.

• Cost-effectiveness/impact: Selective interventions demonstrated an immediate impact (e.g., immunization, HIV, TB, malaria) but exhibited low sustainability when disconnected from universal systems and the social determinants of health.

• Inequalities & policy: Privatization, regulatory capture, and donor dependency deepen inequities in the Global South (Brazil, Mexico, India); threaten health as a right and as a common good.

Why It Matters

The essay shows that what is “ending” is not just funding: it is the collective imagination that, for three decades, sustained cooperation, interdependence, and a civilizational horizon — health as a right. When vertical campaigns replace systems, we save today only to lose tomorrow: numbers shine, networks fray, and the gaps fall on the most vulnerable.

The pandemic only tore away the veil: lives saved with wartime urgency, debts contracted at market speed. The promise of universalization turned into performance, while care became a geopolitical asset. Reframing health as the language of another world — rooted in territory, prevention, participation — is less nostalgia than survival. In the end, beyond indicators, there are bodies, and politics decides who breathes.

What Changes in Practice

Health/Regulation – Reorient funding toward universal systems (strong PHC, workforce, territorial surveillance); shield public governance from private conditionalities; regional pacts for pooled procurement, local production, and technology transfer.

Industry/Innovation – Prioritize appropriate innovation (low complexity, locally maintainable, open data); align impact metrics with systemic results (continuity of care, equity) rather than focusing on “quick wins.”

Society/Environment – Integrate sanitation, nutrition, education, and climate into care; binding social participation; anti-capture policies and active transparency to reduce power asymmetries in agenda-setting.

Scenarios and Next Steps

Short term (1–2 years): Map critical dependencies per country; regional bridging funds; rebuild primary care and surveillance with multidisciplinary teams; anti-capture clauses in procurement and PPPs.

Medium term (3–5 years): Regional R&D and production consortia (vaccines, supplies, essential drugs); legal frameworks for health sovereignty; performance metrics rewarding integration and equity.

Long-term (5–10 years): A multipolar global health architecture with stable financing and public governance; universal systems resilient to shocks (health, climate, and political); a measurable reduction in territorial inequities.

The Takeaway

Campaigns save numbers; systems save lives.

For Further Reading:

The Essentials

Type/Scope
Public policy analysis of the European Union’s revised Tobacco Excise Directive (TED/TTD), focusing on combustible tobacco vs. lower-risk alternatives (vapes, heated products, pouches).

Key Figures

• United Kingdom: Smoking rates dropped from 20.2% (2011) to 11.9% (2023); among 18–24-year-olds, from 25.7% to 9.8%.

• New Zealand: Daily smoking fell from 16.4% (2011) to 6.9% (2023); daily vaping rose to 11.1%.

• UK Disposable Vape Use: Rose from ~1.2% to 22.2% between January 2021 and April 2022; among 18-year-olds, from 0.4% to 54%.

• Sweden: Daily smoking rates below 5%, with cancer incidence 41% lower than the EU average, linked to widespread use of snus and nicotine pouches.

• Illicit Market: In 2024, ~38.9 billion illicit cigarettes were consumed in the EU (9.2% of total), causing €14.9 billion in lost revenue. France led with 18.7 billion illegal units, followed by the Netherlands (17.9% of national consumption) and Spain (1.4 billion).

• Price Elasticity: In New Zealand, the cross-elasticity of 0.16 between vapes and cigarettes; the availability of e-cigarettes reduced cigarette consumption by 42.8%.

Economics

• EU member states collect ~€70 billion annually from tobacco taxes.

• The TED draft expands the tax net to include e-cigarettes, heated tobacco, nicotine pouches, and even raw tobacco under track & trace.

• Cigarettes remain highly taxed, but non-combustible alternatives risk losing their price advantage if minimums rise too close to combustible levels.

• Elasticity studies show that higher prices on vapes can drive users back to cigarettes, counteracting harm reduction goals.

• Small producers of alternatives face disproportionate burdens compared to large multinationals, which benefit from regulatory ambiguity.

Equity and Politics

• The rhetoric is framed in terms of prevention and harmonization, but fiscal dependence dominates.

• Neutralizing price differentials penalizes smokers seeking less harmful options, especially low-income populations.

• Evidence shows access to safer alternatives reduces smoking, yet EU policy flattens risk levels under “precaution.”

• Rising prices risk fueling illicit trade, already significant in several member states.

• For citizens, taxation extends state power into daily micro-decisions, while vulnerable groups—youth, the poor—become collateral damage.

Why It Matters

The TED revision exposes a moral choice disguised as a fiscal technicality:

• To align taxes with proportional risk, encouraging substitution toward less harmful products.

• Or to flatten distinctions, treating unequal risks as equal, turning prevention into dogma, and public health into accounting.

Evidence from Sweden, the UK, and New Zealand shows that when alternatives are accessible and socially legitimate, smoking declines—along with health system burdens. Penalizing those alternatives deepens inequalities, traps the poor, and strengthens illicit markets.

Evidence-based policy, in this context, becomes a pragmatic act of compassion: reducing harm where life actually happens.

The Takeaway

The TED is more than a tax directive: it is a choice between revenue management and harm reduction. Aligning taxation with proportional risk makes fiscal policy a lever for health equity; flattening distinctions only sustains smoking, smuggling, and inequality.

For Further Reading
Read the full analysis here:

Source: Framework Convention on Tobacco Control – COP Process (2006–2025)

The Essentials

• Study/Policy focus: Analysis of COP decisions under the WHO Framework Convention on Tobacco Control (FCTC) from 2006–2024, highlighting how harm reduction was progressively excluded.

• Main finding: Over successive COPs, language shifted from cautious exploration (COP4, 2010) to explicit rejection of reduced-risk products (COP7–COP10), treating them as equivalent to cigarettes.

• Economic/policy outcome: This stance has hindered the implementation of regulated harm-reduction strategies, despite empirical evidence of their effectiveness in countries such as the UK, Sweden, Japan, and New Zealand.

• Impact evaluation: By refusing to differentiate risk, the FCTC’s approach may inadvertently perpetuate smoking prevalence, sustaining the economic and health costs of combustion.

• Equity & human rights: The exclusion of lower-risk alternatives disproportionately harms vulnerable populations unable to quit through abstinence alone, raising ethical concerns about autonomy and the right to health.

Why It Matters

The FCTC’s defensive posture, designed to shield policymaking from tobacco industry interference, has hardened into a doctrine that excludes not only corporate influence but also scientific complexity, independent voices, and pragmatic policy innovation.

This orthodoxy has turned “precaution” into “denial,” and now into “silencing,” leaving millions of smokers without access to less harmful options. When regulatory language collapses nuance into prohibition, public health risks become faith-driven rather than evidence-driven. And the human cost is measured in the persistence of combustion — the leading preventable cause of death worldwide.

What Changes in Practice

Health/Regulation – Without risk differentiation, regulations treat all nicotine products as equally harmful, closing the door on integrated cessation and harm-reduction strategies.

Industry/Innovation – By conflating “industry” with “innovation,” the COP discourages independent research and development, regulatory oversight, and the development of safer technologies.

Society/Environment – Excluding consumer voices silences those most affected: people who continue smoking. Public debate narrows, while illicit markets and unregulated products expand.

Scenarios and Next Steps

Short term (1–2 years): COP11 (Geneva, Nov 2025) likely to reaffirm prohibitionist language. Advocacy efforts may push for transparency, observer access, and debate on harm reduction.

Medium-term (3–5 years): Some member states may diverge — integrating vaping, Heat-not-burn products, or snus/pouches into national cessation strategies despite FCTC guidance, potentially creating policy fractures.

Long term (5–10 years): Unless recalibrated, the COP risks irrelevance: countries could bypass its framework, leaving the Convention stranded in doctrinal isolation while science and practice evolve.

The Takeaway

By refusing to hear, the COP defends orthodoxy but abandons smokers — and silence keeps combustion alive.

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/fctc-silencing

Source: International Journal of Environmental Research and Public Health (2024–2025)

The Essentials

• Study type & scope: Analysis of 20 disposable e-cigarettes in Mexico (Svarch-Pérez et al., 2024), claiming extreme levels of benzene, toluene, and xylene (BTX).

• Main finding (critique): Core methodological errors — unit miscalculations, invalid exposure comparisons, and exaggerated scaling — inflated reported BTX levels by up to 100,000 times.

• Economic/policy outcome: Instead of informing policy, the flawed study risked misleading regulators and wasting resources on exaggerated alarms.

• Impact evaluation: An independent critique by Sussman, Gómez-Ruiz, and Farsalinos found the study’s results and conclusions to be invalid, recommending retraction.

• Equity & trust: Highlights systemic failures in peer review and editorial oversight, threatening the credibility of science in sensitive health debates.

Why It Matters

This episode underscores the fragility of public trust in science. When flawed evidence is published in reputable journals, it risks distorting regulation, misguiding public opinion, and undermining genuine public health efforts. The critique is not a defense of vaping but a defense of rigor — a reminder that science without precision becomes performance.

Behind every unit conversion and every calibration lies a social responsibility: policies, risks, and lives hinge on such details. When rigor collapses, what is lost is not just accuracy but the very trust that makes science meaningful.

What Changes in Practice

Health/Regulation – Regulatory bodies should resist impact-driven claims and demand reproducibility, transparency, and alignment with exposure science standards.

Industry/Innovation – Legitimate toxicological assessments of nicotine products must be performed by qualified labs with validated protocols, ensuring credibility for both consumers and innovators.

Society/Environment – The narrative on chemical risks must account for background exposures (ambient BTX levels) to realistically contextualize risks, thereby avoiding misplaced alarmism.

Scenarios and Next Steps

Short term (1–2 years): Retractions, corrections, and adoption of stricter peer-review protocols for chemical exposure studies.

Medium term (3–5 years): Creation of standardized, internationally accepted methods for analyzing vaping aerosols and contextualizing findings within environmental exposure baselines.

Long term (5–10 years): Rebuilding public trust through systemic reform in scientific publishing — privileging reproducibility and rigor over sensational impact.

The Takeaway

When science loses precision, it doesn’t just fail in the lab — it risks failing society.

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/flawed-vaping-study

Source: National Youth Tobacco Survey (NYTS), JAMA Network Open (2024), FDA reports, Washington Post (2025)

The Essentials

• U.S. youth e-cigarette use fell from 27.5% in 2019 to 7.8% in 2024 among high school students.

• Nicotine pouches emerged as the second most used product among teenagers (1.8% overall, 2.4% in high school).

• Public health debate split: Leana Wen warns of adolescent neurotoxicity, rising use, and aggressive marketing; Matthew Holman (PMI) cites FDA approval of 20 ZYN products, low initiation risk, and benefits for adult substitution.

• Brad Rodu challenges “dual use” narratives, pointing to NHIS data showing large shares of former smokers among vapers and arguing that risk-equivalence messaging blocks harm-reduction progress.

• Ethical and regulatory crossroads: precautionary principle vs. harm-reduction pragmatism, with justice and youth protection as central stakes.

Why It Matters

Nicotine pouches symbolize a new phase in tobacco control: the shift from smoke to smoke-free forms. For some, they are a Trojan horse threatening adolescents; for others, a bridge to safer ground for millions of smokers. The clash is not merely epidemiological—it is narrative, political, and ethical.

Public health stands between zero-risk prevention and harm-reduction pragmatism. How we frame the pouch—emerging epidemic or harm-reduction tool—will shape regulation, inequality, and the very future of nicotine use. The core issue is not only what we inhale or absorb, but the stories that justify whether we punish, permit, or protect.

What Changes in Practice

Health/Regulation – Policies must balance substitution benefits for adults with strict safeguards for youth: age limits, advertising restrictions, and compositional standards.

Industry/Innovation – Tobacco and nicotine companies pivot from combustion to smokeless formats, seeking regulatory legitimacy while requiring independent oversight to avoid self-policing.

Society/Environment – Narratives of “risk” and “safety” redefine how adolescents, parents, and policymakers perceive nicotine, reshaping cultural and ethical attitudes toward addiction.

Scenarios and Next Steps

Short term (1–2 years): Intensified surveillance of youth pouch use; debates around marketing restrictions and product labeling.

Medium term (3–5 years): Integration of nicotine pouches into harm-reduction strategies in some countries; divergence across jurisdictions between prohibitionist and pragmatic approaches.

Long term (5–10 years): Potential displacement of combustible tobacco in high-income nations; persistent global inequalities where regulation lags, and narratives harden along ideological lines.

The Takeaway

“The fight against tobacco is no longer about one enemy, but about how we narrate—and regulate—the shifting forms of risk.”

For Further Reading

Read the full analysis here → claudioteixeira.substack.com/p/nicotine-pouches